ENPP1 deficiency and ABCC6 deficiency
Inozyme Pharma Inc. focuses on inherited disorders linked to disrupted pyrophosphate metabolism, with research centered on ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) deficiency and ATP-binding cassette sub-family C member 6 (ABCC6) deficiency. Its clinical program addresses both isolated and overlapping forms of these rare mineralization disorders.
- ENPP1 deficiency
- ABCC6 deficiency
- Combined ENPP1 or ABCC6 deficiency
The research activity in this area is directed toward conditions associated with abnormal tissue calcification and impaired regulation of inorganic pyrophosphate (PPi).
Generalized arterial calcification of infancy
Clinical research includes generalized arterial calcification of infancy (GACI), a severe pediatric calcification disorder linked to early vascular involvement. The sponsor’s trials examine disease manifestations in infants affected by ENPP1-related pathology.
- Infantile arterial calcification
- Vascular mineralization
- Cardiovascular calcification disorders
This area reflects a therapeutic interest in rare childhood conditions with progressive arterial and cardiac complications.
Pseudoxanthoma elasticum
Another major focus is pseudoxanthoma elasticum (PXE), a hereditary disorder characterized by abnormal mineralization of elastic tissues. The sponsor’s studies extend to the cutaneous, ocular, and vascular consequences of this condition.
- Pseudoxanthoma elasticum (PXE)
- Elastic tissue calcification
- Hereditary mineralization disorders
Research in PXE aligns with a broader interest in diseases involving ectopic calcification and connective tissue involvement.
Bone and skeletal abnormalities
The sponsor also studies skeletal manifestations associated with ENPP1 deficiency, including abnormalities of bone development and mineralization. Trial activity includes assessment of skeletal abnormalities and related structural outcomes in pediatric patients.
- Skeletal mineralization defects
- Bone development abnormalities
- Pediatric skeletal disease
This therapeutic domain connects rare genetic calcification disorders with musculoskeletal involvement.
Cardiovascular and survival outcomes
Several studies address the cardiovascular consequences of ENPP1 deficiency, including heart dysfunction, arterial calcification, and survival-related outcomes in infants and children. The research portfolio includes monitoring of overall survival alongside measures of cardiovascular disease burden.
- Heart dysfunction
- Arterial calcification
- Survival in pediatric rare disease
These investigations place emphasis on severe early-onset complications of mineralization disorders affecting the cardiovascular system.
